Category: Causes and Risk Factors

Lung Cancer Updates from 2017 ASCO Annual Meeting

Each year in early June the American Society for Clinical Oncology holds its Annual Meeting (called simply “ASCO”) in Chicago. The theme for the 2017 meeting was “Making a Difference in Cancer Care WITH YOU.” Over 39,000 cancer researchers, clinicians, patient advocates, and industry representatives from around the world gathered to discuss the latest scientific… Read More

Posted by Janet Freeman-Daily on July 26th, 2017

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

Liquid Biopsy Test Approved by the FDA for EGFR+ Lung Cancer

On June 1, 2016 the US Food and Drug Administration (FDA) approved the first ever blood test to aid clinical decision making for targeted therapies for lung cancer. This blood test, a companion diagnostic called Cobas EGFR Mutation Test v2, allows the detection of mutations in the EGFR (Epidermal Growth Factor Receptor) gene, such as… Read More

Posted by Dr. Guneet Walia on September 29th, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

Cancer Patients Value Quality of Life Over Symptom Management

In October at their headquarters in New York City, CancerCare, a national organization that provides free support and financial services to anyone touched by cancer, held a roundtable discussion on “Improving the Quality of Life for Lung Cancer Patients”. It featured key opinion leaders and lung cancer advocates who discussed the importance of an all-inclusive… Read More

Posted by Dr. Guneet Walia on March 10th, 2016

Lung Cancer in Women: Lets do something about it!

Bonnie J. Addario Lung Cancer Foundation partners with the American Lung Association to fund $250,000 on innovative and transformational research to defeat lung cancer in women An unfortunate and often unknown fact is that lung cancer is the leading cancer killer in women, estimated to be the cause of 1 in 4 female cancer deaths… Read More

Posted by Dr. Guneet Walia on February 25th, 2016

Today is World Cancer Day. Here’s how YOU can #BeTheSolution!

Bonnie J. Addario Lung Cancer Foundation Launches $180,000 Crowdsourcing Challenge to Increase Clinical Trial Patient Enrollment. Each year, in honor of World Cancer Day, the Bonnie J. Addario Lung Cancer Foundation (ALCF) launches a unique, international crowdsourcing challenge that leverages the power of the crowd, encouraging innovators from both within and more importantly, outside healthcare… Read More

Posted by Dr. Guneet Walia on February 4th, 2016

Breakthrough Medicines Usher in Hopeful Era for Lung Cancer Patients

The Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the medical research community and the U.S. Food and Drug Administration (FDA) for putting a heightened focus on lung cancer diagnostics and treatments. ALCF works everyday to educate patients and their families on the latest advancements, encourage participation in clinical trials and fund life-saving research on… Read More

Posted by Dr. Guneet Walia on December 18th, 2015

New treatment approved for drug-resistant lung cancer

Tagrisso approved for EGFR T790M mutation positive NSCLC patients In another win for lung cancer patients, the Food and Drug Administration today granted accelerated approval to Tagrisso (Osimertinib or AZD9291 manufactured by AstraZeneca) this morning for patients whose disease has progressed on EGFR-targeted therapies, and whose tumors express a specific mutation in EGFR- the T790M… Read More

Posted by Dr. Guneet Walia on November 13th, 2015

Got Young Lungs?

In July, 2014 we launched an international study to understand why young people under the age of 40 were increasingly being diagnosed with lung cancer- the Genomics of Young Lung study, the FIRST ever study to prospectively characterize the clinical characteristics and genomic alterations of young lung cancer. Our early data shows that 75% of all patients under 40 have… Read More

Posted by Dr. Guneet Walia on October 5th, 2015